KARO PHARMA DOUBLES SALES AND EARNINGS IN THE FIRST QUARTER

INTERIM REPORT JANUARY – MARCH 2018 ·Net sales amounted to MSEK 267.1 (139.3), equivalent to an increase of 91.7%. Growth was mainly due to acquisitions. ·Organic growth was +10.7%, whereof pharmaceuticals +18.8% and other products +4% ·The gross margin was 56.8% (53.7%) for the period. ·EBITDA amounted to MSEK 88.7 (43.7), which corresponds to a margin of 33.3% (31.4%) ·Earnings per share was SEK 0.45 (0.27) ·Cash and other short-term investments amounted to MSEK 295.2 (166.1) at the end of the period. ·A rights issue to partly finance the